Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.
about
Beta-lactamase inhibitors from laboratory to clinicStructural Basis of the Inhibition of Class A β-Lactamases and Penicillin-Binding Proteins by 6-β-IodopenicillanateNew advances in the use of antimicrobial agents in surgery: intra-abdominal infections.Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactamClinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be.Assessment of biliary excretion of piperacillin-tazobactam in humansDiverse potential of beta-lactamase inhibitors to induce class I enzymes.Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobesEfficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess modelComparative activity of several antimicrobial agents against nosocomial Gram-negative rods isolated across Canada.Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.Role of the beta-lactamase of Campylobacter jejuni in resistance to beta-lactam agents.Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.Antimicrobial therapy for the elderly patient.Mechanisms of beta-lactam resistance in Haemophilus influenzae.Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.SHV-5, a novel SHV-type beta-lactamase that hydrolyzes broad-spectrum cephalosporins and monobactams.Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assaysIn vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria.Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.Piperacillin/tazobactam in complicated urinary tract infections.
P2860
Q24617277-CC497727-1F84-40A2-AB03-D753F556C611Q27658217-01E3C6F3-619E-4A0F-A527-639E0A2B22FFQ33840063-D3BB7DCA-9A92-4A62-B84C-512A635E01F2Q34743287-64AE00C3-D151-4953-82EF-CA49D61C82E6Q35121815-AF616B4D-952A-4651-A633-94888273175CQ35132969-29204DE5-B832-4E03-AB50-16FB3DB34AB1Q35137461-41D8B5C1-FAC4-4E68-8033-A7451F49082FQ35246938-B7B93E47-9AF5-48B4-AA2B-DA87CDBC8115Q35252346-34EC154A-A343-43BA-9261-11263388A20DQ35343060-349A0343-384E-4ABF-8EF9-A031A3894031Q35360429-BA92C466-9C76-4352-B6EC-1C1A1BA41154Q35563877-72246520-1501-4BE8-B897-F8A66BB2C1FCQ35565871-5F0E95D3-59A8-43E2-8197-D7D3B8562FB2Q35575783-8836DD79-B4B7-4036-ADA1-90156035C83EQ35810773-F30B2B15-CFB6-47F1-9CC2-A38B106FB458Q35816718-CBCFF2E4-46A0-46E1-A778-CEE43910C754Q35820623-1733B0F8-00C2-4582-8B7B-77F9F5E01F7CQ35896975-F694EE3F-C9DD-459B-8328-AEC2A07C89F7Q36753643-1A999B61-4B62-437F-AFA4-E98669BC22ACQ36758337-1C021C5B-E38B-46F2-A292-F1D07C705808Q37731521-DDC121B6-71B9-427D-947C-BF82C4C99C8AQ38006505-716E7848-09A9-4C58-AC3D-614D70133A6DQ39607419-1FF86F62-D49D-46FA-9B23-739ACFEB1284Q39815796-DCDF2CFC-4662-41BC-B749-298C76AB55D9Q39817435-40153873-3B3E-4427-B353-6CC3348D4CBCQ39818370-BD43433A-F10C-441B-BF88-273E2DCA7D3FQ40284079-C8361CD3-3B4E-4EC9-AC62-D0D85B92D178Q40284915-B0CE6DF0-30FE-405D-BA72-58E10E7FD44EQ40471195-E6FB62E7-785A-4255-B3A1-BF0837892955Q40923467-9827733A-52CF-404F-8937-0FAC0CBA0B8AQ41610058-69F03B3F-F92F-4048-A757-77577933248CQ44309116-0D5A8464-9E4D-42B9-9805-5187FEE3F71DQ54200563-2223626A-3ED2-4BB1-B084-ED0139E468A7Q54246543-8587A24A-EC51-48B7-BBF2-92357495B999Q54346131-8340F03B-311E-42A0-B005-3056612D9A38Q54350866-FA05F454-8FC3-4054-A70B-0E80BCCE054BQ54631175-8BF9AABE-E574-40D4-9E42-589659F55CD9
P2860
Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Comparative evaluation of a ne ...... rboring known beta-lactamases.
@en
type
label
Comparative evaluation of a ne ...... rboring known beta-lactamases.
@en
prefLabel
Comparative evaluation of a ne ...... rboring known beta-lactamases.
@en
P2093
P2860
P356
P1476
Comparative evaluation of a ne ...... rboring known beta-lactamases.
@en
P2093
P2860
P304
P356
10.1128/AAC.29.5.955
P407
P577
1986-05-01T00:00:00Z